Gilead Sciences Inc. is experiencing a notable uptick in its stock price following a significant collaboration announcement.
Gilead Sciences Inc. (NASDAQ:GILD) is rising today, with shares up by 2.03% to close at CA$150.92. This increase follows the announcement of a strategic partnership with Vir Biotechnology aimed at developing innovative cancer therapies.
Investor takeaway: Investors are responding positively to Gilead's collaboration with Vir Biotechnology, which could enhance its oncology portfolio and drive future growth.
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$207.72B
Div. yield
1.91%
Div. / share
$3.25
52W high
$175.65
52W low
$114.31
1W change
+9.60%
Beta
0.37
Analyst Price Targets
Based on 28 analysts covering GILD · as of Nov 4, 2026
Wall Street analysts forecast GILD stock price to fall 1.1% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$172.50
-1.1% Upside
Previously C$170.88 on Nov 2, 2026
Current Price
C$174.48
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
30.0%
Annualized
90-Day Vol
28.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$208.59
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$185.18 | C$166.98 – C$205.36 |
| 60 trading days | C$196.54 | C$169.79 – C$227.50 |
| 90 trading days | C$208.59 | C$174.38 – C$249.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Gilead's stock rises 2.03%
The stock's increase reflects investor optimism surrounding Gilead's new collaboration, which could unlock significant revenue opportunities in the oncology market.
Bull case
The partnership with Vir Biotechnology could lead to groundbreaking cancer treatments, potentially increasing Gilead's market share in the oncology sector and boosting long-term revenue.
Bear case
Despite the positive news, Gilead's recent history of losses raises concerns about its financial stability and ability to sustain growth amid increasing competition in the biotech space.
Strategic Collaboration with Vir Biotechnology
Gilead announced a licensing agreement with Vir Biotechnology to develop dual-masked T-cell engagers for solid tumors. This collaboration is valued at up to $1.9 billion and is expected to leverage both companies' strengths in oncology research and development.
Market Reaction and Future Outlook
The market has reacted positively to the news, reflecting investor confidence in Gilead's ability to innovate within the competitive oncology space. As Gilead continues to build its cancer treatment portfolio, this partnership could significantly enhance its growth prospects.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
